If your understanding of hormone replacement therapy is shaped by headlines from 20 years ago, it’s time for an update. The 2002 Women’s Health Initiative (WHI) study sent shockwaves through medicine, leading millions of women to abandon HRT and a generation of physicians to stop prescribing it. But the decades since have brought dramatic clarity: the WHI’s findings were widely misinterpreted, and the resulting fear of HRT caused immeasurable harm to women who could have benefited from treatment.
Today, major medical organizations including the North American Menopause Society, the Endocrine Society, and the American College of Obstetricians and Gynecologists affirm that HRT is safe and effective for most women experiencing menopause symptoms, particularly when started within 10 years of menopause onset.
Luvo’s hormone replacement program is built on this modern evidence base. With 10 medication options spanning estradiol formulations, testosterone therapy, and non-hormonal alternatives, it offers a level of treatment personalization that most competitors simply can’t match.
Menopause isn’t a single event — it’s a transition that typically spans several years. The process begins in perimenopause, usually in the mid-40s, when the ovaries begin producing less estrogen and progesterone. Hormone levels fluctuate unpredictably, causing symptoms that can range from mildly annoying to severely disruptive.
Menopause is officially reached when 12 consecutive months pass without a menstrual period, typically around age 51. At this point, the ovaries have largely ceased producing estrogen, and levels of this hormone remain permanently low.
Estrogen isn’t just a reproductive hormone. It has receptors throughout the body — in the brain, bones, cardiovascular system, urogenital tract, skin, and joints. When estrogen declines, the effects cascade across multiple systems: vasomotor symptoms like hot flashes and night sweats, sleep disruption, mood changes and cognitive fog, vaginal dryness and urogenital atrophy, bone density loss, cardiovascular risk changes, joint pain and muscle loss, and skin and hair changes.
Testosterone also declines in women, though more gradually. By menopause, a woman’s testosterone level may be half what it was in her 20s, contributing to decreased libido, reduced energy, and loss of muscle mass.
HRT addresses these declines by restoring hormones to levels that alleviate symptoms and protect long-term health.
What sets Luvo apart from competitors like Hims, Willow, or Pomegranate is the breadth of our medication options. Managing hormonal decline isn’t one-size-fits-all, and neither is our program.
Estradiol is available in five formulations: oral tablets for systemic hormone delivery, transdermal cream for absorption through the skin, transdermal patches for steady-state hormone levels, vaginal gel for localized urogenital symptom relief, and vaginal tablets for targeted vaginal atrophy treatment.
Testosterone for women is available in three formulations: injection, oral tablets, and topical gel — addressing the often-overlooked role of testosterone in female vitality, libido, and body composition.
Non-hormonal options include Paroxetine, the only FDA-approved non-hormonal treatment for vasomotor symptoms, and Desvenlafaxine, an SNRI with strong evidence for hot flash reduction. These serve women who cannot or prefer not to use hormonal therapy.
This 10-medication toolkit means your Luvo provider can design a protocol precisely matched to your symptoms, health history, preferences, and risk profile.
HRT is most clearly indicated for women experiencing moderate to severe vasomotor symptoms such as hot flashes and night sweats, women under 60 or within 10 years of menopause onset (the “window of opportunity” for cardiovascular and bone benefits), women with premature ovarian insufficiency or early menopause (before age 40), women with significant urogenital symptoms like vaginal dryness, painful intercourse, or recurrent UTIs, and women at elevated risk for osteoporosis.
HRT may require additional evaluation or alternatives for women with a history of breast cancer, women with active cardiovascular disease or a history of blood clots, women with undiagnosed vaginal bleeding, and women with active liver disease.
Luvo’s providers conduct thorough health evaluations to determine the safest and most effective approach for each patient. For women who cannot use estrogen, our non-hormonal options provide meaningful symptom relief.
Explore Luvo’s full hormone replacement program to learn more.
